title: Phenotypic screening: the future of antibody discovery.
abstract: Most antibody therapeutics have been isolated from high throughput target-based screening. However, as the number of validated targets diminishes and the target space becomes increasingly competitive, alternative strategies, such as phenotypic screening, are gaining momentum. Here, we review successful phenotypic screens, including those used to isolate antibodies against cancer and infectious agents. We also consider exciting advances in the expression and phenotypic screening of antibody repertoires in single cell autocrine systems. As technologies continue to develop, we believe that antibody phenotypic screening will increase further in popularity and has the potential to provide the next generation of therapeutic antibodies.
authors.affiliation: Department of Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK.
authors.forename: Andrea L
authors.initials: AL
authors.lastname: Gonzalez-Munoz
authors.affiliation: Department of Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK.
authors.forename: Ralph R
authors.initials: RR
authors.lastname: Minter
authors.affiliation: Department of Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK. Electronic address: rusts@medimmune.com.
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Rust
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology* / Q000627:therapeutic use*; D055808:Drug Discovery / Q000379:methods; D006801:Humans; D008403:Mass Screening / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy; D010641:Phenotype
chemical_list: D000906:Antibodies